Karuna Pharmaceuticals nabs $42 mln Series A
Boston-based Karuna Pharmaceuticals, which is focused on targeting muscarinic receptors for treating disorders marked by psychosis and cognitive impairment, has secured $42 million Series A financing. The investors included ARCH Venture Partners.
3 August 2018•1 min read
